Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis

Overall, these results indicate that in a large, global registry, most patients with atherothrombosis would not have been eligible for SPRINT and were rarely being treated to a systolic BP < 120 mm Hg. Further dedicated investigation is warranted to determine the optimal BP target in this vulnerable patient population.